Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SL-325 in Moderately to Severely Active Crohn's Disease
NCT07753850Phase 2Recruiting
- Sponsor
- Shattuck Labs
- Start
- Oct 2026
- Primary completion
- Jul 2028
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of SL-325 in Crohn's disease (4 arms), sponsored by Shattuck Labs. Primary endpoint: Proportion of participants who achieve endoscopic response at 12 weeks. Started Oct 2026; status: recruiting.
02
Drugs
SL-325
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on NCT07753850.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07753850.